Chelating compound, chrysoidine, is more effective in both antiprion activity and brain endothelial permeability than quinacrine

Cellular and Molecular Neurobiology

Volumn 27, Issue 3, 2007, Pages 303-316

  Doh Ura, Katsumi ^a   Tamura, Kazuhiko ^b   Karube, Yoshiharu ^b   Naito, Mikihiko ^c   Tsuruo, Takashi ^c   Kataoka, Yasufumi ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Aromatic azo compounds; Blood brain barrier; Brain endothelial cells; Chelating agents; Chrysoidine; Prion; Prion infected neuroblastoma cells; Therapy

Indexed keywords

1 (2 THIAZOLYLAZO) 2 NAPHTHOL; 1 PYRID 2 YLAZO 2 NAPHTHOL; 2 PHENYLAZO 4 METHYLPHENOL; 4 (2 PYRIDYLAZO)RESORCINOL; 4 (2 THIAZOLYLAZO)RESORCINOL; 4 METHYL 2 (2 THIAZOLYLAZO)PHENOL; 4 METHYL 5 SULFOMETHYLAMINO 2 (2 THIAZOLYLAZO)BENZOIC ACID; 5 BROMO 2 (2 PYRIDYLAZO) 5 [N PROPYL N (3 SULFOPROPYL)AMINO]PHENOL; 5 BROMO 2 (2 PYRIDYLAZO) 5 DIETHYLAMINOPHENOL; 5 CHLORO 2 (2 PYRIDYLAZO) 5 DIETHYLAMINOPHENOL; AZO COMPOUND; BENZENE; BENZOIC ACID DERIVATIVE; CHELATING AGENT; CHRYSOIDINE; CONGO RED; MEPACRINE; NAPHTHALENE; NAPHTHOL DERIVATIVE; PHENOL DERIVATIVE; PHENYLAZORESORCINOL; RESORCINOL DERIVATIVE; UNCLASSIFIED DRUG; YELLOW AB;

ANIMAL CELL; ANIMAL MODEL; ANTIPRION ACTIVITY; ARTICLE; BRAIN; BRAIN CAPILLARY; CELL MEMBRANE PERMEABILITY; CHELATION; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIUM CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM;

ANIMALS; BRAIN; CELL MEMBRANE PERMEABILITY; CHELATING AGENTS; DRUG EVALUATION, PRECLINICAL; ENDOTHELIAL CELLS; MICE; MODELS, BIOLOGICAL; P-AMINOAZOBENZENE; PRION DISEASES; PRIONS; PROTEIN BINDING; PRPSC PROTEINS; QUINACRINE; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 34248512609     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10571-006-9122-0     Document Type: Article

References (19)

1. Anomymous. (1975). Chrysoidine. Int. Agency Res. Cancer Monogr. 8:91-96.
2. Brown, D. R. (2004). Metallic prions. Biochem. Soc. Symp. 71:193-202.
3. Cartwright, R. A., Robinson, M. R. G., Glashan, R. W., Gray, B. K., Hamilton-Stewart, P., Cartwright, S. C., and Barnham-Hall, D. (1983). Does the use of stained maggots present a risk of bladder cancer to coarse fishermen? Carcinogenesis 4:111-113.
4. Dehouck, M. P., Jolliet-Riant, P., Brée, F., Fruchart, J. C., Cecchelli, R., and Tillement, J. P. (1992). Drug transfer across the blood-brain barrier: Correlation between in vitro and in vivo models. J. Neurochem. 58:1790-1797.
5. Dohgu, S., Yamauchi, A., Takata, F., Sawada, Y., Higuchi, S., Naito, M., Tsuruo, T., Shirabe, S., Niwa, M., Katamine, S., and Kataoka, Y. (2004). Uptake and efflux of quinacrine, a candidate for the treatment of prion diseases, at the blood-brain barrier. Cell. Mol. Neurobiol. 24:205-217.
6. Doh-Ura, K., Iwaki, T., and Caughey, B. (2000). Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J. Virol. 74:4894-4897.
7. Frostell-Karlsson, A., Remaeus, A., Roos, H., Andersson, K., Borg, P., Hamalainen, M., and Karlsson, R. (2000). Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels. J. Med. Chem. 43:1986-1992.
8. Ishikawa, K., Doh-ura, K., Kudo, Y., Nishida, N., Murakami-Kubo, I., Ando, Y., Sawada, T., and Iwaki, T. (2004). Amyloid imaging probes are useful for detection of prion plaques and treatment of transmissible spongiform encephalopathies. J. Gen. Virol. 85:1785-1790.
9. Kawatake, S., Nishimura, Y., Sakaguchi, S., Iwaki, T., and Doh-ura, K. (2006). Surface plasmon resonance analysis for the screening of anti-prion compounds. Biol. Pharm. Bull. 29:927-932.
10. Kim, C.-L., Karino, A., Ishiguro, N., Shinagawa, M., Sato, M., and Horiuchi, M. (2004). Cell-surface retention of PrPC by anti-PrP antibody prevents protease-resistant PrP formation. J. Gen. Virol. 85:3473-3482.
11. Klunk, W. E., Bacskai, B. J., Mathis, C. A., Kajdasz, S. T., McLellan, M. E., Frosch, M. P., Debnath, M.L., Holt, D. P., Wang, Y., and Hyman, B. T. (2002). Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 61:797-805.
12. Murakami-Kubo, I., Doh-Ura, K., Ishikawa, K., Kawatake, S., Sasaki, K., Kira, J., Ohta, S., and Iwaki, T. (2004). Quinoline derivatives are therapeutic candidates for transmissible spongiform encephalopathies. J. Virol. 78:1281-1288.
13. Nakajima, M., Yamada, T., Kusuhara, T., Furukawa, H., Takahashi, M., Yamauchi, A., and Kataoka, Y. (2004). Results of quinacrine administration to patients with Creutzfeldt-Jakob disease. Dement. Geriatr. Cogn. Disord. 17:158-163.
14. Prusiner, S. B. (1991). Molecular biology of prion diseases. Science 252:1515-1522.
15. Race, R. E., Caughey, B., Graham, K., Ernst, D., and Chesebro, B. (1988). Analyses of frequency of infection, specific infectivity, and prion protein biosynthesis in scrapie-infected neuroblastoma cell clones. J. Virol. 62:2845-2849.
16. Sandhu, P., and Chipman, J. K. (1990). Bacterial mutagenesis and hepatocyte unscheduled DNA synthesis induced by chrysoidine azo-dye components. Mutat. Res. 240:227-236.
17. Sole, G., and Sorahan, T. (1985). Coarse fishing and risk of urothelial cancer. Lancet 1:1477-1479.
18. Sorahan, T., and Sole, G. (1990). Coarse fishing and urothelial cancer: A regional case-control study. Br. J. Cancer 62:138-141.
19. Tatsuta, T., Naito, M., Oh-hara, T., Sugawara, I., and Tsuruo, T. (1992). Functional involvement of Pglycoprotein in blood-brain barrier. J. Biol. Chem. 267:20383-20391.